Nektar Therapeutics
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ITH0.MU | PODD | NVO | ZEAL.CO | BBNX | LRMR | |
|---|---|---|---|---|---|---|
| Market cap | — | 11.44B | 180.71B | 15.73B | 951.86M | 286.72M |
| P/E (TTM) | — | 27.0 | 10.3 | 6.1 | — | — |
| Forward P/E | — | 21.4 | 11.9 | 33.3 | -8.0 | -2.6 |
| Price/book | — | 7.7 | 5.5 | 0.9 | 2.4 | 2.3 |
| Dividend yield | — | — | 4.26% | — | — | — |
| 1-year change | −32.00% | −48.97% | −9.31% | −44.17% | −32.31% | −20.46% |
| Today | 0.00% | +6.56% | −2.83% | +0.08% | +3.29% | +8.66% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All ITH0.MU news ›Nektar Therapeutics: Focus Returns To The Strengths Of The Company
Nektar’s rezpegaldesleukin enters phase 3 in atopic dermatitis, with Q1 2027 data ahead. Discover more here on NKTR and our bullish thesis for the stock. - Nektar Therapeutic's rezpegaldesleukin is now in phase 3 trials in atopic…
Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink Partners
Posted by Sarita Garza on Oct 13th, 2026 Leerink Partners assumed coverage on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report released on Monday morning, Marketbeat Ratings reports. The brokerage issued an…
BTIG reiterates Buy rating on Nektar Therapeutics, $178 price target
BTIG reiterated their Buy rating on Nektar Therapeutics's stock with a price target of $178.00. The price target implies an upside of 336.3% from the Oct 8 close of $40.80. Positive Initial Legal Outcomes: The favorable outcome of the…
Nektar Therapeutics (NKTR) Shareholder/Analyst Call - Slideshow
(NASDAQ:NKTR) 2026-10-03 Seeking Alpha The following slide deck was published by Nektar Therapeutics in conjunction with this event.
Reviewing Verastem (NASDAQ:VSTM) and Nektar Therapeutics (NASDAQ:NKTR)
Posted by Michael Walen on Oct 4th, 2026 Verastem (NASDAQ:VSTM – Get Free Report) and Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com2
- themarketsdaily.com2
- tradingview.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 5 articles, not a forecast.